Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)—are…
Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 FDA…
Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 EMA…
The large size of the HER2-positive breast cancer market in Europe, driven by high incidence and long treatment duration with expensive agents, is of great commercial interest to drug developers…
Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology's coverage of painful diabetic neuropathy (PDN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology's coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…
Clarivate Epidemiology's coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…
Clarivate Epidemiology's coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…
Clarivate Epidemiology's coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
asdfasfasdfasdfasdfasdf
The chronic obstructive pulmonary disease market is becoming increasingly crowded, and market access in the EU5 is a growing concern as manufacturers attempt to achieve favorable reimbursement…
asdfasdfasfasdfasdfasdf
Hema Text node 1
Herma Text node